Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs

47Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Despite advances in antimicrobial therapy and intensive care support, Staphylococcus aureus continues to cause significant morbidity and mortality. We studied community-acquired S. aureus bacteraemia in a population where intravenous drug abuse is extremely uncommon, prospectively reviewing all such patients (n = 113) admitted to Groote Schuur Hospital from February 1986 to January 1991. Overall mortality was 35%. Factors associated with poor outcome were: confusion on presentation, failure to mount a febrile response, acute renal failure, adult respiratory distress syndrome, shock, endocarditis, disseminated intravascular coagulation and platelet count of < 100 x 109/l. Only confusion, acute renal failure and shock were independently associated with death by stepwise regression analysis. Skin infections were the most commonly identified source of bacteraemia (22%), but in 58% of patients the source was not determined. Twenty-six percent of patients were diabetic. Almost all patients (90%) developed one or more complications. In those who survived, therapy was generally prolonged, with a median of 70 days and range of 7-393 days, depending on the associated complications. Community-acquired S. aureus bacteraemia is a serious condition associated with a high complication rate and mortality.

Cite

CITATION STYLE

APA

Willcox, P. A., Rayner, B. L., & Whitelaw, D. A. (1998). Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs. QJM: An International Journal of Medicine, 91(1), 41–47. https://doi.org/10.1093/qjmed/91.1.41

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free